Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.20 -0.06 (-0.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data 
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the Jefferies Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
$9.6M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Recap: Akero Therapeutics Q3 Earnings
Akero Therapeutics (NASDAQ:AKRO) reported its Q3 earnings results on Friday, November 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise
 
Via Benzinga
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
From Akero Therapeutics
Via GlobeNewswire
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
The battle pits 89bio and Akero in nonalcoholic steatohepatitis. 
Via Investor's Business Daily
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Akero Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
 
Via Benzinga
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
20 Favorite Biotech & Medical Stocks For 2023
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program
 
Via Benzinga
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
From Akero Therapeutics
Via GlobeNewswire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks 
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category 
From Akero Therapeutics
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
From Akero Therapeutics
Via GlobeNewswire
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.